Lung adenocarcinoma with EGFR exon 19 insertion identified using a compact panel and its response to osimertinib: a
Mika Horie1, Kazuhisa Nakashima1, Kojiro Hata1
1Department of Internal Medicine, Division of Medical Oncology and Respiratory Medicine, Shimane University Faculty of Medicine, 89-1 Enya-cho, Izumo, Shimane, 693-8501, Japan.
Abstract:
An 80-year-old man underwent a left lower lobectomy for lung adenocarcinoma. Next-generation sequencing in a clinical trial identified an epidermal growth factor receptor (EGFR) exon 19 insertion (exon19ins), which was not detected by the Oncomine™ Dx Target Test®, a companion diagnostic tool for EGFR mutations. However, the Lung Cancer Compact Panel® Dx (LCCP), another companion diagnostic tool, confirmed exon19ins. Osimertinib was administered, which led to a slight tumor response. This case suggests that LCCP may be useful in detecting rare EGFR mutations and that osimertinib may be effective against exon19ins.
Insights
A rare epidermal growth factor receptor (EGFR) exon 19 insertion in lung adenocarcinoma was detected by the Lung Cancer Compact Panel® Dx (LCCP), not another test. Osimertinib showed a slight tumor response, suggesting LCCP
Area of Science:
- Oncology
- Molecular Diagnostics
- Thoracic Surgery
Background:
- Lung adenocarcinoma diagnosis and treatment rely on accurate molecular profiling.
- Epidermal growth factor receptor (EGFR) mutations are key targets for lung cancer therapy.
- Companion diagnostic tools are crucial for identifying actionable mutations.
